Global Next Generation Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029
The global Next Generation Monoclonal Antibodies market size is expected to reach $ 47260 million by 2029, rising at a market growth of 19.4% CAGR during the forecast period (2023-2029).
The Next Generation Monoclonal Antibodies Market is driven by the ongoing evolution of biopharmaceuticals and the remarkable potential of advanced monoclonal antibodies to treat an array of diseases, including cancer, autoimmune disorders, and infectious diseases. These next-generation antibodies offer enhanced therapeutic benefits through improved target specificity, reduced immunogenicity, and novel mechanisms of action. As precision medicine and biopharmaceutical innovations advance, the demand for next-generation monoclonal antibodies continues to surge. Innovations in antibody engineering, design, and production technologies further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, high production costs, and evolving regulatory standards while ensuring accessibility and affordability for patients. Overcoming research and development challenges, optimizing manufacturing processes, and adapting to changing healthcare regulations are ongoing hurdles. Additionally, the market faces competition from traditional antibodies and other biologic therapies, necessitating continuous innovation to unlock the full therapeutic potential of next-generation monoclonal antibodies. Striking a balance between providing safe, effective, and accessible next-generation monoclonal antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Next Generation Monoclonal Antibodies Market.
Evolution of monoclonal antibodies has resulted in the next generation of antibody therapeutics, with engineering to enhance characteristics such as target cell–killing potency. These include antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and nanobodies.
This report studies the global Next Generation Monoclonal Antibodies demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Next Generation Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Next Generation Monoclonal Antibodies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Next Generation Monoclonal Antibodies total market, 2018-2029, (USD Million)
Global Next Generation Monoclonal Antibodies total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Next Generation Monoclonal Antibodies total market, key domestic companies and share, (USD Million)
Global Next Generation Monoclonal Antibodies revenue by player and market share 2018-2023, (USD Million)
Global Next Generation Monoclonal Antibodies total market by Type, CAGR, 2018-2029, (USD Million)
Global Next Generation Monoclonal Antibodies total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Next Generation Monoclonal Antibodies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Gilead Sciences and GSK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Next Generation Monoclonal Antibodies market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Next Generation Monoclonal Antibodies Market, By Region:
1. How big is the global Next Generation Monoclonal Antibodies market?
2. What is the demand of the global Next Generation Monoclonal Antibodies market?
3. What is the year over year growth of the global Next Generation Monoclonal Antibodies market?
4. What is the total value of the global Next Generation Monoclonal Antibodies market?
5. Who are the major players in the global Next Generation Monoclonal Antibodies market?
The Next Generation Monoclonal Antibodies Market is driven by the ongoing evolution of biopharmaceuticals and the remarkable potential of advanced monoclonal antibodies to treat an array of diseases, including cancer, autoimmune disorders, and infectious diseases. These next-generation antibodies offer enhanced therapeutic benefits through improved target specificity, reduced immunogenicity, and novel mechanisms of action. As precision medicine and biopharmaceutical innovations advance, the demand for next-generation monoclonal antibodies continues to surge. Innovations in antibody engineering, design, and production technologies further contribute to market expansion. However, a significant challenge for this market is the need to address complex drug development processes, high production costs, and evolving regulatory standards while ensuring accessibility and affordability for patients. Overcoming research and development challenges, optimizing manufacturing processes, and adapting to changing healthcare regulations are ongoing hurdles. Additionally, the market faces competition from traditional antibodies and other biologic therapies, necessitating continuous innovation to unlock the full therapeutic potential of next-generation monoclonal antibodies. Striking a balance between providing safe, effective, and accessible next-generation monoclonal antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Next Generation Monoclonal Antibodies Market.
Evolution of monoclonal antibodies has resulted in the next generation of antibody therapeutics, with engineering to enhance characteristics such as target cell–killing potency. These include antibody–drug conjugates (ADCs), bispecific antibodies, engineered antibodies, antibody fragments, and nanobodies.
This report studies the global Next Generation Monoclonal Antibodies demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Next Generation Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Next Generation Monoclonal Antibodies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Next Generation Monoclonal Antibodies total market, 2018-2029, (USD Million)
Global Next Generation Monoclonal Antibodies total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Next Generation Monoclonal Antibodies total market, key domestic companies and share, (USD Million)
Global Next Generation Monoclonal Antibodies revenue by player and market share 2018-2023, (USD Million)
Global Next Generation Monoclonal Antibodies total market by Type, CAGR, 2018-2029, (USD Million)
Global Next Generation Monoclonal Antibodies total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Next Generation Monoclonal Antibodies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Takeda, Daiichi Sankyo, Seagen, Astellas, Gilead Sciences and GSK, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Next Generation Monoclonal Antibodies market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Next Generation Monoclonal Antibodies Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Antibody Drug Conjugate (ADC)
- Bispecific Antibody (BsAb)
- Antibody-radionuclide Conjugates
- Immune Diseases
- Cancer
- Other
- Roche
- Amgen
- Pfizer
- Takeda
- Daiichi Sankyo
- Seagen
- Astellas
- Gilead Sciences
- GSK
- Immunocore
- ADC Therapeutics
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- AbbVie
1. How big is the global Next Generation Monoclonal Antibodies market?
2. What is the demand of the global Next Generation Monoclonal Antibodies market?
3. What is the year over year growth of the global Next Generation Monoclonal Antibodies market?
4. What is the total value of the global Next Generation Monoclonal Antibodies market?
5. Who are the major players in the global Next Generation Monoclonal Antibodies market?
1 SUPPLY SUMMARY
1.1 Next Generation Monoclonal Antibodies Introduction
1.2 World Next Generation Monoclonal Antibodies Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Next Generation Monoclonal Antibodies Total Market by Region (by Headquarter Location)
1.3.1 World Next Generation Monoclonal Antibodies Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.3 China Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.4 Europe Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.5 Japan Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.6 South Korea Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.7 ASEAN Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.8 India Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Next Generation Monoclonal Antibodies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Next Generation Monoclonal Antibodies Major Market Trends
2 DEMAND SUMMARY
2.1 World Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.2 World Next Generation Monoclonal Antibodies Consumption Value by Region
2.2.1 World Next Generation Monoclonal Antibodies Consumption Value by Region (2018-2023)
2.2.2 World Next Generation Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029)
2.3 United States Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.4 China Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.5 Europe Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.6 Japan Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.7 South Korea Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.8 ASEAN Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.9 India Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
3 WORLD NEXT GENERATION MONOCLONAL ANTIBODIES COMPANIES COMPETITIVE ANALYSIS
3.1 World Next Generation Monoclonal Antibodies Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Next Generation Monoclonal Antibodies Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Next Generation Monoclonal Antibodies in 2022
3.2.3 Global Concentration Ratios (CR8) for Next Generation Monoclonal Antibodies in 2022
3.3 Next Generation Monoclonal Antibodies Company Evaluation Quadrant
3.4 Next Generation Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.4.1 Next Generation Monoclonal Antibodies Market: Region Footprint
3.4.2 Next Generation Monoclonal Antibodies Market: Company Product Type Footprint
3.4.3 Next Generation Monoclonal Antibodies Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Next Generation Monoclonal Antibodies Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Next Generation Monoclonal Antibodies Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Next Generation Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Next Generation Monoclonal Antibodies Consumption Value Comparison
4.2.1 United States VS China: Next Generation Monoclonal Antibodies Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Next Generation Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Next Generation Monoclonal Antibodies Companies and Market Share, 2018-2023
4.3.1 United States Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023)
4.4 China Based Companies Next Generation Monoclonal Antibodies Revenue and Market Share, 2018-2023
4.4.1 China Based Next Generation Monoclonal Antibodies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023)
4.5 Rest of World Based Next Generation Monoclonal Antibodies Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Next Generation Monoclonal Antibodies Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antibody Drug Conjugate (ADC)
5.2.2 Bispecific Antibody (BsAb)
5.2.3 Antibody-radionuclide Conjugates
5.3 Market Segment by Type
5.3.1 World Next Generation Monoclonal Antibodies Market Size by Type (2018-2023)
5.3.2 World Next Generation Monoclonal Antibodies Market Size by Type (2024-2029)
5.3.3 World Next Generation Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Next Generation Monoclonal Antibodies Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Immune Diseases
6.2.2 Cancer
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Next Generation Monoclonal Antibodies Market Size by Application (2018-2023)
6.3.2 World Next Generation Monoclonal Antibodies Market Size by Application (2024-2029)
6.3.3 World Next Generation Monoclonal Antibodies Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Next Generation Monoclonal Antibodies Product and Services
7.1.4 Roche Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Amgen
7.2.1 Amgen Details
7.2.2 Amgen Major Business
7.2.3 Amgen Next Generation Monoclonal Antibodies Product and Services
7.2.4 Amgen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Amgen Recent Developments/Updates
7.2.6 Amgen Competitive Strengths & Weaknesses
7.3 Pfizer
7.3.1 Pfizer Details
7.3.2 Pfizer Major Business
7.3.3 Pfizer Next Generation Monoclonal Antibodies Product and Services
7.3.4 Pfizer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Pfizer Recent Developments/Updates
7.3.6 Pfizer Competitive Strengths & Weaknesses
7.4 Takeda
7.4.1 Takeda Details
7.4.2 Takeda Major Business
7.4.3 Takeda Next Generation Monoclonal Antibodies Product and Services
7.4.4 Takeda Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Takeda Recent Developments/Updates
7.4.6 Takeda Competitive Strengths & Weaknesses
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Details
7.5.2 Daiichi Sankyo Major Business
7.5.3 Daiichi Sankyo Next Generation Monoclonal Antibodies Product and Services
7.5.4 Daiichi Sankyo Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Daiichi Sankyo Recent Developments/Updates
7.5.6 Daiichi Sankyo Competitive Strengths & Weaknesses
7.6 Seagen
7.6.1 Seagen Details
7.6.2 Seagen Major Business
7.6.3 Seagen Next Generation Monoclonal Antibodies Product and Services
7.6.4 Seagen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Seagen Recent Developments/Updates
7.6.6 Seagen Competitive Strengths & Weaknesses
7.7 Astellas
7.7.1 Astellas Details
7.7.2 Astellas Major Business
7.7.3 Astellas Next Generation Monoclonal Antibodies Product and Services
7.7.4 Astellas Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Astellas Recent Developments/Updates
7.7.6 Astellas Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Next Generation Monoclonal Antibodies Product and Services
7.8.4 Gilead Sciences Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 GSK
7.9.1 GSK Details
7.9.2 GSK Major Business
7.9.3 GSK Next Generation Monoclonal Antibodies Product and Services
7.9.4 GSK Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 GSK Recent Developments/Updates
7.9.6 GSK Competitive Strengths & Weaknesses
7.10 Immunocore
7.10.1 Immunocore Details
7.10.2 Immunocore Major Business
7.10.3 Immunocore Next Generation Monoclonal Antibodies Product and Services
7.10.4 Immunocore Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Immunocore Recent Developments/Updates
7.10.6 Immunocore Competitive Strengths & Weaknesses
7.11 ADC Therapeutics
7.11.1 ADC Therapeutics Details
7.11.2 ADC Therapeutics Major Business
7.11.3 ADC Therapeutics Next Generation Monoclonal Antibodies Product and Services
7.11.4 ADC Therapeutics Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 ADC Therapeutics Recent Developments/Updates
7.11.6 ADC Therapeutics Competitive Strengths & Weaknesses
7.12 Bayer
7.12.1 Bayer Details
7.12.2 Bayer Major Business
7.12.3 Bayer Next Generation Monoclonal Antibodies Product and Services
7.12.4 Bayer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Bayer Recent Developments/Updates
7.12.6 Bayer Competitive Strengths & Weaknesses
7.13 Novartis
7.13.1 Novartis Details
7.13.2 Novartis Major Business
7.13.3 Novartis Next Generation Monoclonal Antibodies Product and Services
7.13.4 Novartis Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Novartis Recent Developments/Updates
7.13.6 Novartis Competitive Strengths & Weaknesses
7.14 Lantheus
7.14.1 Lantheus Details
7.14.2 Lantheus Major Business
7.14.3 Lantheus Next Generation Monoclonal Antibodies Product and Services
7.14.4 Lantheus Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Lantheus Recent Developments/Updates
7.14.6 Lantheus Competitive Strengths & Weaknesses
7.15 Aurobindo Pharma
7.15.1 Aurobindo Pharma Details
7.15.2 Aurobindo Pharma Major Business
7.15.3 Aurobindo Pharma Next Generation Monoclonal Antibodies Product and Services
7.15.4 Aurobindo Pharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Aurobindo Pharma Recent Developments/Updates
7.15.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.16 Mundipharma
7.16.1 Mundipharma Details
7.16.2 Mundipharma Major Business
7.16.3 Mundipharma Next Generation Monoclonal Antibodies Product and Services
7.16.4 Mundipharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Mundipharma Recent Developments/Updates
7.16.6 Mundipharma Competitive Strengths & Weaknesses
7.17 AbbVie
7.17.1 AbbVie Details
7.17.2 AbbVie Major Business
7.17.3 AbbVie Next Generation Monoclonal Antibodies Product and Services
7.17.4 AbbVie Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 AbbVie Recent Developments/Updates
7.17.6 AbbVie Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Next Generation Monoclonal Antibodies Industry Chain
8.2 Next Generation Monoclonal Antibodies Upstream Analysis
8.3 Next Generation Monoclonal Antibodies Midstream Analysis
8.4 Next Generation Monoclonal Antibodies Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Next Generation Monoclonal Antibodies Introduction
1.2 World Next Generation Monoclonal Antibodies Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Next Generation Monoclonal Antibodies Total Market by Region (by Headquarter Location)
1.3.1 World Next Generation Monoclonal Antibodies Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.3 China Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.4 Europe Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.5 Japan Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.6 South Korea Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.7 ASEAN Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.3.8 India Next Generation Monoclonal Antibodies Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Next Generation Monoclonal Antibodies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Next Generation Monoclonal Antibodies Major Market Trends
2 DEMAND SUMMARY
2.1 World Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.2 World Next Generation Monoclonal Antibodies Consumption Value by Region
2.2.1 World Next Generation Monoclonal Antibodies Consumption Value by Region (2018-2023)
2.2.2 World Next Generation Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029)
2.3 United States Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.4 China Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.5 Europe Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.6 Japan Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.7 South Korea Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.8 ASEAN Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
2.9 India Next Generation Monoclonal Antibodies Consumption Value (2018-2029)
3 WORLD NEXT GENERATION MONOCLONAL ANTIBODIES COMPANIES COMPETITIVE ANALYSIS
3.1 World Next Generation Monoclonal Antibodies Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Next Generation Monoclonal Antibodies Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Next Generation Monoclonal Antibodies in 2022
3.2.3 Global Concentration Ratios (CR8) for Next Generation Monoclonal Antibodies in 2022
3.3 Next Generation Monoclonal Antibodies Company Evaluation Quadrant
3.4 Next Generation Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.4.1 Next Generation Monoclonal Antibodies Market: Region Footprint
3.4.2 Next Generation Monoclonal Antibodies Market: Company Product Type Footprint
3.4.3 Next Generation Monoclonal Antibodies Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Next Generation Monoclonal Antibodies Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Next Generation Monoclonal Antibodies Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Next Generation Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Next Generation Monoclonal Antibodies Consumption Value Comparison
4.2.1 United States VS China: Next Generation Monoclonal Antibodies Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Next Generation Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Next Generation Monoclonal Antibodies Companies and Market Share, 2018-2023
4.3.1 United States Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023)
4.4 China Based Companies Next Generation Monoclonal Antibodies Revenue and Market Share, 2018-2023
4.4.1 China Based Next Generation Monoclonal Antibodies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023)
4.5 Rest of World Based Next Generation Monoclonal Antibodies Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Next Generation Monoclonal Antibodies Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Antibody Drug Conjugate (ADC)
5.2.2 Bispecific Antibody (BsAb)
5.2.3 Antibody-radionuclide Conjugates
5.3 Market Segment by Type
5.3.1 World Next Generation Monoclonal Antibodies Market Size by Type (2018-2023)
5.3.2 World Next Generation Monoclonal Antibodies Market Size by Type (2024-2029)
5.3.3 World Next Generation Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Next Generation Monoclonal Antibodies Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Immune Diseases
6.2.2 Cancer
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Next Generation Monoclonal Antibodies Market Size by Application (2018-2023)
6.3.2 World Next Generation Monoclonal Antibodies Market Size by Application (2024-2029)
6.3.3 World Next Generation Monoclonal Antibodies Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Next Generation Monoclonal Antibodies Product and Services
7.1.4 Roche Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Amgen
7.2.1 Amgen Details
7.2.2 Amgen Major Business
7.2.3 Amgen Next Generation Monoclonal Antibodies Product and Services
7.2.4 Amgen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Amgen Recent Developments/Updates
7.2.6 Amgen Competitive Strengths & Weaknesses
7.3 Pfizer
7.3.1 Pfizer Details
7.3.2 Pfizer Major Business
7.3.3 Pfizer Next Generation Monoclonal Antibodies Product and Services
7.3.4 Pfizer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Pfizer Recent Developments/Updates
7.3.6 Pfizer Competitive Strengths & Weaknesses
7.4 Takeda
7.4.1 Takeda Details
7.4.2 Takeda Major Business
7.4.3 Takeda Next Generation Monoclonal Antibodies Product and Services
7.4.4 Takeda Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Takeda Recent Developments/Updates
7.4.6 Takeda Competitive Strengths & Weaknesses
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Details
7.5.2 Daiichi Sankyo Major Business
7.5.3 Daiichi Sankyo Next Generation Monoclonal Antibodies Product and Services
7.5.4 Daiichi Sankyo Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Daiichi Sankyo Recent Developments/Updates
7.5.6 Daiichi Sankyo Competitive Strengths & Weaknesses
7.6 Seagen
7.6.1 Seagen Details
7.6.2 Seagen Major Business
7.6.3 Seagen Next Generation Monoclonal Antibodies Product and Services
7.6.4 Seagen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Seagen Recent Developments/Updates
7.6.6 Seagen Competitive Strengths & Weaknesses
7.7 Astellas
7.7.1 Astellas Details
7.7.2 Astellas Major Business
7.7.3 Astellas Next Generation Monoclonal Antibodies Product and Services
7.7.4 Astellas Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Astellas Recent Developments/Updates
7.7.6 Astellas Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Next Generation Monoclonal Antibodies Product and Services
7.8.4 Gilead Sciences Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 GSK
7.9.1 GSK Details
7.9.2 GSK Major Business
7.9.3 GSK Next Generation Monoclonal Antibodies Product and Services
7.9.4 GSK Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 GSK Recent Developments/Updates
7.9.6 GSK Competitive Strengths & Weaknesses
7.10 Immunocore
7.10.1 Immunocore Details
7.10.2 Immunocore Major Business
7.10.3 Immunocore Next Generation Monoclonal Antibodies Product and Services
7.10.4 Immunocore Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Immunocore Recent Developments/Updates
7.10.6 Immunocore Competitive Strengths & Weaknesses
7.11 ADC Therapeutics
7.11.1 ADC Therapeutics Details
7.11.2 ADC Therapeutics Major Business
7.11.3 ADC Therapeutics Next Generation Monoclonal Antibodies Product and Services
7.11.4 ADC Therapeutics Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 ADC Therapeutics Recent Developments/Updates
7.11.6 ADC Therapeutics Competitive Strengths & Weaknesses
7.12 Bayer
7.12.1 Bayer Details
7.12.2 Bayer Major Business
7.12.3 Bayer Next Generation Monoclonal Antibodies Product and Services
7.12.4 Bayer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Bayer Recent Developments/Updates
7.12.6 Bayer Competitive Strengths & Weaknesses
7.13 Novartis
7.13.1 Novartis Details
7.13.2 Novartis Major Business
7.13.3 Novartis Next Generation Monoclonal Antibodies Product and Services
7.13.4 Novartis Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Novartis Recent Developments/Updates
7.13.6 Novartis Competitive Strengths & Weaknesses
7.14 Lantheus
7.14.1 Lantheus Details
7.14.2 Lantheus Major Business
7.14.3 Lantheus Next Generation Monoclonal Antibodies Product and Services
7.14.4 Lantheus Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Lantheus Recent Developments/Updates
7.14.6 Lantheus Competitive Strengths & Weaknesses
7.15 Aurobindo Pharma
7.15.1 Aurobindo Pharma Details
7.15.2 Aurobindo Pharma Major Business
7.15.3 Aurobindo Pharma Next Generation Monoclonal Antibodies Product and Services
7.15.4 Aurobindo Pharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Aurobindo Pharma Recent Developments/Updates
7.15.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.16 Mundipharma
7.16.1 Mundipharma Details
7.16.2 Mundipharma Major Business
7.16.3 Mundipharma Next Generation Monoclonal Antibodies Product and Services
7.16.4 Mundipharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Mundipharma Recent Developments/Updates
7.16.6 Mundipharma Competitive Strengths & Weaknesses
7.17 AbbVie
7.17.1 AbbVie Details
7.17.2 AbbVie Major Business
7.17.3 AbbVie Next Generation Monoclonal Antibodies Product and Services
7.17.4 AbbVie Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 AbbVie Recent Developments/Updates
7.17.6 AbbVie Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Next Generation Monoclonal Antibodies Industry Chain
8.2 Next Generation Monoclonal Antibodies Upstream Analysis
8.3 Next Generation Monoclonal Antibodies Midstream Analysis
8.4 Next Generation Monoclonal Antibodies Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Next Generation Monoclonal Antibodies Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Next Generation Monoclonal Antibodies Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Next Generation Monoclonal Antibodies Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Next Generation Monoclonal Antibodies Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Next Generation Monoclonal Antibodies Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Next Generation Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Next Generation Monoclonal Antibodies Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Next Generation Monoclonal Antibodies Players in 2022
Table 12. World Next Generation Monoclonal Antibodies Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Next Generation Monoclonal Antibodies Company Evaluation Quadrant
Table 14. Head Office of Key Next Generation Monoclonal Antibodies Player
Table 15. Next Generation Monoclonal Antibodies Market: Company Product Type Footprint
Table 16. Next Generation Monoclonal Antibodies Market: Company Product Application Footprint
Table 17. Next Generation Monoclonal Antibodies Mergers & Acquisitions Activity
Table 18. United States VS China Next Generation Monoclonal Antibodies Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Next Generation Monoclonal Antibodies Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Next Generation Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 23. China Based Next Generation Monoclonal Antibodies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Next Generation Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 26. Rest of World Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Next Generation Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 29. World Next Generation Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Next Generation Monoclonal Antibodies Market Size by Type (2018-2023) & (USD Million)
Table 31. World Next Generation Monoclonal Antibodies Market Size by Type (2024-2029) & (USD Million)
Table 32. World Next Generation Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Next Generation Monoclonal Antibodies Market Size by Application (2018-2023) & (USD Million)
Table 34. World Next Generation Monoclonal Antibodies Market Size by Application (2024-2029) & (USD Million)
Table 35. Roche Basic Information, Area Served and Competitors
Table 36. Roche Major Business
Table 37. Roche Next Generation Monoclonal Antibodies Product and Services
Table 38. Roche Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Roche Recent Developments/Updates
Table 40. Roche Competitive Strengths & Weaknesses
Table 41. Amgen Basic Information, Area Served and Competitors
Table 42. Amgen Major Business
Table 43. Amgen Next Generation Monoclonal Antibodies Product and Services
Table 44. Amgen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Amgen Recent Developments/Updates
Table 46. Amgen Competitive Strengths & Weaknesses
Table 47. Pfizer Basic Information, Area Served and Competitors
Table 48. Pfizer Major Business
Table 49. Pfizer Next Generation Monoclonal Antibodies Product and Services
Table 50. Pfizer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Pfizer Recent Developments/Updates
Table 52. Pfizer Competitive Strengths & Weaknesses
Table 53. Takeda Basic Information, Area Served and Competitors
Table 54. Takeda Major Business
Table 55. Takeda Next Generation Monoclonal Antibodies Product and Services
Table 56. Takeda Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Takeda Recent Developments/Updates
Table 58. Takeda Competitive Strengths & Weaknesses
Table 59. Daiichi Sankyo Basic Information, Area Served and Competitors
Table 60. Daiichi Sankyo Major Business
Table 61. Daiichi Sankyo Next Generation Monoclonal Antibodies Product and Services
Table 62. Daiichi Sankyo Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Daiichi Sankyo Recent Developments/Updates
Table 64. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 65. Seagen Basic Information, Area Served and Competitors
Table 66. Seagen Major Business
Table 67. Seagen Next Generation Monoclonal Antibodies Product and Services
Table 68. Seagen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Seagen Recent Developments/Updates
Table 70. Seagen Competitive Strengths & Weaknesses
Table 71. Astellas Basic Information, Area Served and Competitors
Table 72. Astellas Major Business
Table 73. Astellas Next Generation Monoclonal Antibodies Product and Services
Table 74. Astellas Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Astellas Recent Developments/Updates
Table 76. Astellas Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Next Generation Monoclonal Antibodies Product and Services
Table 80. Gilead Sciences Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. GSK Basic Information, Area Served and Competitors
Table 84. GSK Major Business
Table 85. GSK Next Generation Monoclonal Antibodies Product and Services
Table 86. GSK Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. GSK Recent Developments/Updates
Table 88. GSK Competitive Strengths & Weaknesses
Table 89. Immunocore Basic Information, Area Served and Competitors
Table 90. Immunocore Major Business
Table 91. Immunocore Next Generation Monoclonal Antibodies Product and Services
Table 92. Immunocore Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Immunocore Recent Developments/Updates
Table 94. Immunocore Competitive Strengths & Weaknesses
Table 95. ADC Therapeutics Basic Information, Area Served and Competitors
Table 96. ADC Therapeutics Major Business
Table 97. ADC Therapeutics Next Generation Monoclonal Antibodies Product and Services
Table 98. ADC Therapeutics Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. ADC Therapeutics Recent Developments/Updates
Table 100. ADC Therapeutics Competitive Strengths & Weaknesses
Table 101. Bayer Basic Information, Area Served and Competitors
Table 102. Bayer Major Business
Table 103. Bayer Next Generation Monoclonal Antibodies Product and Services
Table 104. Bayer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Bayer Recent Developments/Updates
Table 106. Bayer Competitive Strengths & Weaknesses
Table 107. Novartis Basic Information, Area Served and Competitors
Table 108. Novartis Major Business
Table 109. Novartis Next Generation Monoclonal Antibodies Product and Services
Table 110. Novartis Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Novartis Recent Developments/Updates
Table 112. Novartis Competitive Strengths & Weaknesses
Table 113. Lantheus Basic Information, Area Served and Competitors
Table 114. Lantheus Major Business
Table 115. Lantheus Next Generation Monoclonal Antibodies Product and Services
Table 116. Lantheus Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Lantheus Recent Developments/Updates
Table 118. Lantheus Competitive Strengths & Weaknesses
Table 119. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 120. Aurobindo Pharma Major Business
Table 121. Aurobindo Pharma Next Generation Monoclonal Antibodies Product and Services
Table 122. Aurobindo Pharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Aurobindo Pharma Recent Developments/Updates
Table 124. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 125. Mundipharma Basic Information, Area Served and Competitors
Table 126. Mundipharma Major Business
Table 127. Mundipharma Next Generation Monoclonal Antibodies Product and Services
Table 128. Mundipharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Mundipharma Recent Developments/Updates
Table 130. AbbVie Basic Information, Area Served and Competitors
Table 131. AbbVie Major Business
Table 132. AbbVie Next Generation Monoclonal Antibodies Product and Services
Table 133. AbbVie Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 134. Global Key Players of Next Generation Monoclonal Antibodies Upstream (Raw Materials)
Table 135. Next Generation Monoclonal Antibodies Typical Customers
LIST OF FIGURE
Figure 1. Next Generation Monoclonal Antibodies Picture
Figure 2. World Next Generation Monoclonal Antibodies Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Next Generation Monoclonal Antibodies Total Market Size (2018-2029) & (USD Million)
Figure 4. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 13. Next Generation Monoclonal Antibodies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 16. World Next Generation Monoclonal Antibodies Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 18. China Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 23. India Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Next Generation Monoclonal Antibodies by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Next Generation Monoclonal Antibodies Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Next Generation Monoclonal Antibodies Markets in 2022
Figure 27. United States VS China: Next Generation Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Next Generation Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Next Generation Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Next Generation Monoclonal Antibodies Market Size Market Share by Type in 2022
Figure 31. Antibody Drug Conjugate (ADC)
Figure 32. Bispecific Antibody (BsAb)
Figure 33. Antibody-radionuclide Conjugates
Figure 34. World Next Generation Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
Figure 35. World Next Generation Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Next Generation Monoclonal Antibodies Market Size Market Share by Application in 2022
Figure 37. Immune Diseases
Figure 38. Cancer
Figure 39. Other
Figure 40. Next Generation Monoclonal Antibodies Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Table 1. World Next Generation Monoclonal Antibodies Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Next Generation Monoclonal Antibodies Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Next Generation Monoclonal Antibodies Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Next Generation Monoclonal Antibodies Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Next Generation Monoclonal Antibodies Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Next Generation Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Next Generation Monoclonal Antibodies Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Next Generation Monoclonal Antibodies Players in 2022
Table 12. World Next Generation Monoclonal Antibodies Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Next Generation Monoclonal Antibodies Company Evaluation Quadrant
Table 14. Head Office of Key Next Generation Monoclonal Antibodies Player
Table 15. Next Generation Monoclonal Antibodies Market: Company Product Type Footprint
Table 16. Next Generation Monoclonal Antibodies Market: Company Product Application Footprint
Table 17. Next Generation Monoclonal Antibodies Mergers & Acquisitions Activity
Table 18. United States VS China Next Generation Monoclonal Antibodies Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Next Generation Monoclonal Antibodies Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Next Generation Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 23. China Based Next Generation Monoclonal Antibodies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Next Generation Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 26. Rest of World Based Next Generation Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Next Generation Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Next Generation Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 29. World Next Generation Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Next Generation Monoclonal Antibodies Market Size by Type (2018-2023) & (USD Million)
Table 31. World Next Generation Monoclonal Antibodies Market Size by Type (2024-2029) & (USD Million)
Table 32. World Next Generation Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Next Generation Monoclonal Antibodies Market Size by Application (2018-2023) & (USD Million)
Table 34. World Next Generation Monoclonal Antibodies Market Size by Application (2024-2029) & (USD Million)
Table 35. Roche Basic Information, Area Served and Competitors
Table 36. Roche Major Business
Table 37. Roche Next Generation Monoclonal Antibodies Product and Services
Table 38. Roche Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Roche Recent Developments/Updates
Table 40. Roche Competitive Strengths & Weaknesses
Table 41. Amgen Basic Information, Area Served and Competitors
Table 42. Amgen Major Business
Table 43. Amgen Next Generation Monoclonal Antibodies Product and Services
Table 44. Amgen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Amgen Recent Developments/Updates
Table 46. Amgen Competitive Strengths & Weaknesses
Table 47. Pfizer Basic Information, Area Served and Competitors
Table 48. Pfizer Major Business
Table 49. Pfizer Next Generation Monoclonal Antibodies Product and Services
Table 50. Pfizer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Pfizer Recent Developments/Updates
Table 52. Pfizer Competitive Strengths & Weaknesses
Table 53. Takeda Basic Information, Area Served and Competitors
Table 54. Takeda Major Business
Table 55. Takeda Next Generation Monoclonal Antibodies Product and Services
Table 56. Takeda Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Takeda Recent Developments/Updates
Table 58. Takeda Competitive Strengths & Weaknesses
Table 59. Daiichi Sankyo Basic Information, Area Served and Competitors
Table 60. Daiichi Sankyo Major Business
Table 61. Daiichi Sankyo Next Generation Monoclonal Antibodies Product and Services
Table 62. Daiichi Sankyo Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Daiichi Sankyo Recent Developments/Updates
Table 64. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 65. Seagen Basic Information, Area Served and Competitors
Table 66. Seagen Major Business
Table 67. Seagen Next Generation Monoclonal Antibodies Product and Services
Table 68. Seagen Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Seagen Recent Developments/Updates
Table 70. Seagen Competitive Strengths & Weaknesses
Table 71. Astellas Basic Information, Area Served and Competitors
Table 72. Astellas Major Business
Table 73. Astellas Next Generation Monoclonal Antibodies Product and Services
Table 74. Astellas Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Astellas Recent Developments/Updates
Table 76. Astellas Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Next Generation Monoclonal Antibodies Product and Services
Table 80. Gilead Sciences Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. GSK Basic Information, Area Served and Competitors
Table 84. GSK Major Business
Table 85. GSK Next Generation Monoclonal Antibodies Product and Services
Table 86. GSK Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. GSK Recent Developments/Updates
Table 88. GSK Competitive Strengths & Weaknesses
Table 89. Immunocore Basic Information, Area Served and Competitors
Table 90. Immunocore Major Business
Table 91. Immunocore Next Generation Monoclonal Antibodies Product and Services
Table 92. Immunocore Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Immunocore Recent Developments/Updates
Table 94. Immunocore Competitive Strengths & Weaknesses
Table 95. ADC Therapeutics Basic Information, Area Served and Competitors
Table 96. ADC Therapeutics Major Business
Table 97. ADC Therapeutics Next Generation Monoclonal Antibodies Product and Services
Table 98. ADC Therapeutics Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. ADC Therapeutics Recent Developments/Updates
Table 100. ADC Therapeutics Competitive Strengths & Weaknesses
Table 101. Bayer Basic Information, Area Served and Competitors
Table 102. Bayer Major Business
Table 103. Bayer Next Generation Monoclonal Antibodies Product and Services
Table 104. Bayer Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Bayer Recent Developments/Updates
Table 106. Bayer Competitive Strengths & Weaknesses
Table 107. Novartis Basic Information, Area Served and Competitors
Table 108. Novartis Major Business
Table 109. Novartis Next Generation Monoclonal Antibodies Product and Services
Table 110. Novartis Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Novartis Recent Developments/Updates
Table 112. Novartis Competitive Strengths & Weaknesses
Table 113. Lantheus Basic Information, Area Served and Competitors
Table 114. Lantheus Major Business
Table 115. Lantheus Next Generation Monoclonal Antibodies Product and Services
Table 116. Lantheus Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Lantheus Recent Developments/Updates
Table 118. Lantheus Competitive Strengths & Weaknesses
Table 119. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 120. Aurobindo Pharma Major Business
Table 121. Aurobindo Pharma Next Generation Monoclonal Antibodies Product and Services
Table 122. Aurobindo Pharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Aurobindo Pharma Recent Developments/Updates
Table 124. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 125. Mundipharma Basic Information, Area Served and Competitors
Table 126. Mundipharma Major Business
Table 127. Mundipharma Next Generation Monoclonal Antibodies Product and Services
Table 128. Mundipharma Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Mundipharma Recent Developments/Updates
Table 130. AbbVie Basic Information, Area Served and Competitors
Table 131. AbbVie Major Business
Table 132. AbbVie Next Generation Monoclonal Antibodies Product and Services
Table 133. AbbVie Next Generation Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 134. Global Key Players of Next Generation Monoclonal Antibodies Upstream (Raw Materials)
Table 135. Next Generation Monoclonal Antibodies Typical Customers
LIST OF FIGURE
Figure 1. Next Generation Monoclonal Antibodies Picture
Figure 2. World Next Generation Monoclonal Antibodies Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Next Generation Monoclonal Antibodies Total Market Size (2018-2029) & (USD Million)
Figure 4. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Next Generation Monoclonal Antibodies Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Next Generation Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 13. Next Generation Monoclonal Antibodies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 16. World Next Generation Monoclonal Antibodies Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 18. China Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 23. India Next Generation Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Next Generation Monoclonal Antibodies by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Next Generation Monoclonal Antibodies Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Next Generation Monoclonal Antibodies Markets in 2022
Figure 27. United States VS China: Next Generation Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Next Generation Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Next Generation Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Next Generation Monoclonal Antibodies Market Size Market Share by Type in 2022
Figure 31. Antibody Drug Conjugate (ADC)
Figure 32. Bispecific Antibody (BsAb)
Figure 33. Antibody-radionuclide Conjugates
Figure 34. World Next Generation Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
Figure 35. World Next Generation Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Next Generation Monoclonal Antibodies Market Size Market Share by Application in 2022
Figure 37. Immune Diseases
Figure 38. Cancer
Figure 39. Other
Figure 40. Next Generation Monoclonal Antibodies Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
